AstraZeneca's Tagrisso/chemo combo staves off lung cancer for almost nine months. But will side effects limit its use?
Adding chemotherapy to the EGFR-targeted kinase inhibitor Tagrisso delayed disease progression by 8.8 months compared to Tagrisso alone, AstraZeneca reported in the latest push to broaden its reach in lung cancer.
AstraZeneca first scored an FDA approval for Tagrisso monotherapy in 2015 for non-small cell lung cancer, and the drug has since established itself as standard of care in several settings. The Phase III FLAURA2 trial was designed to see if it can also serve as a backbone for combination with chemo, particularly for subgroups of patients who are seeing resistance or less durable response on Tagrisso monotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
